RNA / Avidity Biosciences: Risks And Potential

Avidity Biosciences, Inc. (RNA) came out with a quarterly loss of $0.74 per share versus the Zacks Consensus Estimate of a loss of $0.90. This compare more_horizontal

Avidity Biosciences (RNA) provides an update on its phase I/II study of its lead product candidate AOC 1001 for the treatment of myotonic dystrophy ty more_horizontal

A key study from Avidity Biosciences remains on hold after a patient experienced a rare side effect, leading RNA stock to plummet Thursday. The post A more_horizontal

Shares of Avidity Biosciences Inc. RNA, +0.55% fell about 3.0% in premarket trading on Thursday after the company said a partial clinical hold on its more_horizontal

Avidity Biosciences, Inc. is a leader in antibody Oligonucleotide conjugate technology. This technology enables delivery of Oligonucleotides to muscle more_horizontal

Avidity Biosciences, Inc. (RNA) delivered earnings and revenue surprises of -4.76% and 15.86%, respectively, for the quarter ended December 2022. Do t more_horizontal

Avidity Biosciences possesses the only RNA agent capable of being delivered into the muscle. The company's platform success opens up its pipeline to r more_horizontal

Avidity Biosciences' stock was up 55% last week after releasing preliminary data from a Phase 1/ 2 study of its antibody-oligonucleotide technology ca more_horizontal